CovidV2, new, Analysis, bibRecord, 000811

Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant

Identifieur interne : 000811 ( new/Analysis ); précédent : 000810; suivant : 000812

Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant

Auteurs : E. Lunell [Suède] ; L. Molander [Suède] ; M. Andersson [Suède]

Source :

European Journal of Clinical Pharmacology [ 0031-6970 ] ; 1995-03-01.

RBID : ISTEX:7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C

English descriptors

Abstract

Abstract: The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state. Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of Cmax, AUC and tmax were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72. The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.

Url:

DOI: 10.1007/BF00202176

Affiliations:

Suède

Links to Exploration step

ISTEX:7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title>
<author><name sortKey="Lunell, E" sort="Lunell, E" uniqKey="Lunell E" first="E." last="Lunell">E. Lunell</name>
</author>
<author><name sortKey="Molander, L" sort="Molander, L" uniqKey="Molander L" first="L." last="Molander">L. Molander</name>
</author>
<author><name sortKey="Andersson, M" sort="Andersson, M" uniqKey="Andersson M" first="M." last="Andersson">M. Andersson</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1007/BF00202176</idno>
<idno type="url">https://api.istex.fr/ark:/67375/1BB-PJ4Q91WT-1/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000178</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000178</idno>
<idno type="wicri:Area/Istex/Curation">000146</idno>
<idno type="wicri:Area/Istex/Checkpoint">000446</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000446</idno>
<idno type="wicri:doubleKey">0031-6970:1995:Lunell E:relative:bioavailability:of</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087527</idno>
<idno type="RBID">PMC:7087527</idno>
<idno type="wicri:Area/Pmc/Corpus">000252</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000252</idno>
<idno type="wicri:Area/Pmc/Curation">000252</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000252</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000A50</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A50</idno>
<idno type="wicri:Area/Ncbi/Merge">001658</idno>
<idno type="wicri:Area/Ncbi/Curation">001658</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001658</idno>
<idno type="wicri:doubleKey">0031-6970:1995:Lunell E:relative:bioavailability:of</idno>
<idno type="wicri:Area/Main/Merge">001A55</idno>
<idno type="wicri:Area/Main/Curation">001A39</idno>
<idno type="wicri:Area/Main/Exploration">001A39</idno>
<idno type="wicri:Area/new/Extraction">000811</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant</title>
<author><name sortKey="Lunell, E" sort="Lunell, E" uniqKey="Lunell E" first="E." last="Lunell">E. Lunell</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund</wicri:regionArea>
<wicri:noRegion>Lund</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Pharmacology, University Hospital, Lund</wicri:regionArea>
<wicri:noRegion>Lund</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Molander, L" sort="Molander, L" uniqKey="Molander L" first="L." last="Molander">L. Molander</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Pharmacia Research Laboratories, Karl XI gatan 4, S-222 20, Lund</wicri:regionArea>
<wicri:noRegion>Lund</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Andersson, M" sort="Andersson, M" uniqKey="Andersson M" first="M." last="Andersson">M. Andersson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Oto-rhino-laryngology, University Hospital, Lund</wicri:regionArea>
<wicri:noRegion>Lund</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">European Journal of Clinical Pharmacology</title>
<title level="j" type="abbrev">Eur J Clin Pharmacol</title>
<idno type="ISSN">0031-6970</idno>
<idno type="eISSN">1432-1041</idno>
<imprint><publisher>Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<date type="published" when="1995-03-01">1995-03-01</date>
<biblScope unit="volume">48</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="71">71</biblScope>
<biblScope unit="page" to="75">75</biblScope>
</imprint>
<idno type="ISSN">0031-6970</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0031-6970</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nicotine</term>
<term>Rhinitis</term>
<term>drug interaction</term>
<term>nasal spray</term>
<term>pharmacokinetics</term>
<term>xylometazoline</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adverse events</term>
<term>Baseline nicotine concentration</term>
<term>Bioavailability</term>
<term>Bioequivalence</term>
<term>Bioequivalence ranges</term>
<term>Blood flow</term>
<term>Blood samples</term>
<term>Clin pharmacokinet</term>
<term>Cmax</term>
<term>Concurrent administration</term>
<term>Confidence intervals</term>
<term>Decongestant</term>
<term>Drug administration</term>
<term>First dose</term>
<term>Infectious rhinitis</term>
<term>Intranasal</term>
<term>Intranasal administration</term>
<term>Intranasal nicotine</term>
<term>Minor proportion</term>
<term>Minor reduction</term>
<term>Nasal</term>
<term>Nasal cavity</term>
<term>Nasal discharge</term>
<term>Nasal mucosa</term>
<term>Nasal mucosal blood flow</term>
<term>Nasal nicotine solution</term>
<term>Nasal obstruction</term>
<term>Nasal spray</term>
<term>Nasal vasoconstrictor decongestant</term>
<term>Nicotine</term>
<term>Nicotine absorption</term>
<term>Nicotine behaviour</term>
<term>Nicotine patch</term>
<term>Normal health</term>
<term>Peak concentration</term>
<term>Peak plasma concentration</term>
<term>Pharmacokinetic</term>
<term>Plasma curve</term>
<term>Present study</term>
<term>Rapid absorption</term>
<term>Rhinitis</term>
<term>Rhinitis rhinitis</term>
<term>Rhinitis xylometazoline</term>
<term>Smoking cessation</term>
<term>Smoking cessation products</term>
<term>Tmax</term>
<term>Topical decongestant</term>
<term>University hospital</term>
<term>Vasoconstrictor</term>
<term>Vasoconstrictor xylometazoline</term>
<term>Xylometazoline</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: The relative bioavailability of nicotine from a nasal spray was assessed in 15 smokers suffering a common cold and rhinitis according to generally accepted criteria. The patients were given a single dose of 2 mg nicotine from the nasal spray with and without concurrent administration of a nasal vasoconstrictor decongestant, xylometazoline, in randomised order. Control session measurements were made in the disease-free state. Applying strict bioequivalence criteria, we found that common cold/rhinitis slightly reduced the bioavailability of nicotine, both in its rate and extent; the geometric mean of the ratio of Cmax, AUC and tmax were 0.81, 0.93 and 1.36, respectively. The nasal vasoconstrictor, xylometazoline, normalised the extent of the bioavailability of nicotine, but further prolonged the time for absorption to almost twice that measured in the disease-free state, increasing the tmax ratio to 1.72. The results suggest that a minor proportion of people stopping smoking with the help of a nicotine nasal spray may experience a minor reduction in the effect of the spray during common cold/rhinitis. However, the nicotine self-titration behaviour found with most smoking cessation products (except the nicotine patch) will automatically lead to an adjustment of the dosage to achieve the desired effect.</div>
</front>
</TEI>
<affiliations><list><country><li>Suède</li>
</country>
</list>
<tree><country name="Suède"><noRegion><name sortKey="Lunell, E" sort="Lunell, E" uniqKey="Lunell E" first="E." last="Lunell">E. Lunell</name>
</noRegion>
<name sortKey="Andersson, M" sort="Andersson, M" uniqKey="Andersson M" first="M." last="Andersson">M. Andersson</name>
<name sortKey="Lunell, E" sort="Lunell, E" uniqKey="Lunell E" first="E." last="Lunell">E. Lunell</name>
<name sortKey="Molander, L" sort="Molander, L" uniqKey="Molander L" first="L." last="Molander">L. Molander</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/new/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000811 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/new/Analysis/biblio.hfd -nk 000811 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV2
   |flux=    new
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:7A6BA88EA0887A037CD2DABA7D31B5AAF07F076C
   |texte=   Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant
}}

This area was generated with Dilib version V0.6.33.
Data generation: Sat Mar 28 17:51:24 2020. Site generation: Sun Jan 31 15:35:48 2021

Serveur d'exploration Covid (26 mars)

Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant

Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration Covid (26 mars)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.